Human medicines European public assessment report (EPAR): Rimmyrah, ranibizumab, Date of authorisation: 05/01/2024, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Opzelura, ruxolitinib, Date of authorisation: 19/04/2023, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Ezmekly, mirdametinib, Date of authorisation: 17/07/2025, Status: Authorised

List of signals discussed at PRAC since September 2012

Human medicines European public assessment report (EPAR): Usymro, ustekinumab, Date of authorisation: 14/08/2025, Status: Authorised

Human medicines European public assessment report (EPAR): Riltrava Aerosphere, formoterol fumarate dihydrate,glycopyrronium,budesonide, Date of authorisation: 06/01/2022, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Rystiggo, rozanolixizumab, Date of authorisation: 05/01/2024, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Aucatzyl, obecabtagene autoleucel, Date of authorisation: 17/07/2025, Status: Authorised

Human medicines European public assessment report (EPAR): Ultomiris, ravulizumab, Date of authorisation: 02/07/2019, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Invanz, ertapenem, Date of authorisation: 18/04/2002, Revision: 28, Status: Authorised